The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
A 50-year-old man is referred for evaluation of a rash first noted approximately 2 months ago. He states that the rash is itchy and is accentuated by rubbing and applying pressure. Despite a 2-week course of cetirizine, the condition has not improved. The patient is currently prescribed a thiazide diuretic to control his hypertension. Examination…
Approval was based on results from two phase 2 single-arm, open-label trials that demonstrated overall response rate and duration of response.
Lumasiran is an investigational ribonucleic acid interference therapeutic that inhibits hepatic production of oxalate by targeting hydroxyacid oxidase 1.
Zokinvy works by preventing farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
Drugs in the Pipeline
Results from the final analysis showed that cabotegravir was 66% more effective than FTC/TDF in preventing HIV acquisition.
Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients.
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.